Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Price:
401.08 USD
0.23%
Market Closed
Updated:
May 6, 2024
Vertex Pharmaceuticals Inc
Net Income (Common)
|
Vertex Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
MRNA
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Net Income (Common)
-$4.7B
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Vertex Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
3.6B
USD
3.6B
USD
Based on the financial report for Dec 31, 2023, Vertex Pharmaceuticals Inc's Net Income (Common) amounts to 3.6B USD.
What is Vertex Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
12%
12%
Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for Vertex Pharmaceuticals Inc have been 10% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
